Search research articles
Contact Us
Filters
Showing results (111-120 of 383) with videos related to
Page
of 39
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 1, 2004
Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies
Todd M Zimmerman, Helena Harlin, Olatoyosi M Odenike, et al.
Blood
|
March 8, 2003
Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series
Sonali M Smith, Michelle M Le Beau, Dezheng Huo, et al.
Leukemia Research
|
August 5, 2014
Genomic aberrations in myeloid sarcoma without blood or bone marrow involvement: characterization of formalin-fixed paraffin-embedded samples by chromosomal microarrays
M Kamran Mirza, Madina Sukhanova, Friedrich Stölzel, et al.
Leukemia & Lymphoma
|
April 4, 2013
Patients with chronic lymphocytic leukemia with high-risk genomic features have inferior outcome on successive Cancer and Leukemia Group B trials with alemtuzumab consolidation: subgroup analysis from CALGB 19901 and CALGB 10101
Jeffrey A Jones, Amy S Ruppert, Weiqiang Zhao, et al.
Blood
|
October 24, 2002
Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712)
John C Byrd, Bercedis L Peterson, Vicki A Morrison, et al.
Leukemia & Lymphoma
|
October 14, 2009
Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence
Koen van Besien, Alexander Dew, Shang Lin, et al.
Leukemia & Lymphoma
|
April 15, 2003
Treatment of the chronic phase of chronic myeloid leukemia with an intermittent schedule of recombinant interferon alfa-2b and cytarabine: results from CALGB study 9013
Richard T Silver, Bercedis L Peterson, Ted P Szatrowski, et al.
Leukemia & Lymphoma
|
September 6, 2007
Successful allogeneic transplantation of patients with suspected prior invasive mold infection
Brian T Hill, Lavayna Kondapalli, Andrew Artz, et al.
Cancer Chemotherapy and Pharmacology
|
August 2, 2008
A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804
Richard M Stone, Kathleen A Donohue, Wendy Stock, et al.
Journal of Mammary Gland Biology and Neoplasia
|
October 6, 2023
High-fat diet, but not duration of lactation, increases mammary gland lymphatic vessel function and subsequent growth of inflammatory breast cancer cells
Wintana Balema, Janelle Morton, Richard A Larson, et al.
Page
of 39
Search research articles
Search
Showing results (111-120 of 383) with videos related to
Sort By:
Page
of 39
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 1, 2004
Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies
Todd M Zimmerman, Helena Harlin, Olatoyosi M Odenike, et al.
Blood
|
March 8, 2003
Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series
Sonali M Smith, Michelle M Le Beau, Dezheng Huo, et al.
Leukemia Research
|
August 5, 2014
Genomic aberrations in myeloid sarcoma without blood or bone marrow involvement: characterization of formalin-fixed paraffin-embedded samples by chromosomal microarrays
M Kamran Mirza, Madina Sukhanova, Friedrich Stölzel, et al.
Leukemia & Lymphoma
|
April 4, 2013
Patients with chronic lymphocytic leukemia with high-risk genomic features have inferior outcome on successive Cancer and Leukemia Group B trials with alemtuzumab consolidation: subgroup analysis from CALGB 19901 and CALGB 10101
Jeffrey A Jones, Amy S Ruppert, Weiqiang Zhao, et al.
Blood
|
October 24, 2002
Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712)
John C Byrd, Bercedis L Peterson, Vicki A Morrison, et al.
Leukemia & Lymphoma
|
October 14, 2009
Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence
Koen van Besien, Alexander Dew, Shang Lin, et al.
Leukemia & Lymphoma
|
April 15, 2003
Treatment of the chronic phase of chronic myeloid leukemia with an intermittent schedule of recombinant interferon alfa-2b and cytarabine: results from CALGB study 9013
Richard T Silver, Bercedis L Peterson, Ted P Szatrowski, et al.
Leukemia & Lymphoma
|
September 6, 2007
Successful allogeneic transplantation of patients with suspected prior invasive mold infection
Brian T Hill, Lavayna Kondapalli, Andrew Artz, et al.
Cancer Chemotherapy and Pharmacology
|
August 2, 2008
A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804
Richard M Stone, Kathleen A Donohue, Wendy Stock, et al.
Journal of Mammary Gland Biology and Neoplasia
|
October 6, 2023
High-fat diet, but not duration of lactation, increases mammary gland lymphatic vessel function and subsequent growth of inflammatory breast cancer cells
Wintana Balema, Janelle Morton, Richard A Larson, et al.
Page
of 39